Stock Analysis·← Pickers

DRTSW

Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. (DRTSW) is currently in an uptrend, trading above both the 50-day and 200-day moving averages. RSI is at 56.4, with 3/3 trend checks passing.

Price
$3.25
-0.30 (-8.45%)
Day range
$0.33–$3.38
52wk $0.33–$3.30
Volume
37.0K
Avg
Trend score
3/3
Uptrend
RSI (14)
56.4
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

DRTSW with MA50 and MA200

3.882.972.051.140.2207/0110/0701/2304/2007/16
DRTSW2025-07-012026-07-16
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$2.40+35.15% vs price
MA200
$1.11+191.56% vs price
RSI (14)
56.4Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Valuation

DRTSW valuation multiples (TTM)

P/E Ratio
P/S Ratio
P/B Ratio
EV/EBITDA
Valuation multiples are provided by Financial Modeling Prep when available.
Analyst Ratings

DRTSW analyst consensus

Avg Price Target
High Target
Low Target
Analyst Coverage
Analyst ratings and price targets are provided by Financial Modeling Prep when available.
Chart Summary
Trend summary for DRTSW

Alpha Tau Medical Ltd. (DRTSW) is still trading in a constructive trend overall. The latest available price is $3.25, and 3 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 35.1% and above the 200-day moving average by 191.6%.

Momentum and stretch context

DRTSW currently has an RSI reading of 56.4, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.

What traders may watch next

For traders reviewing DRTSW next, the key question is whether the trend still looks healthy or whether price has started to outrun itself. A strong uptrend can stay strong, but entries often become more difficult when price is already extended, so many traders will watch for pullbacks, support reactions, or fresh bases rather than chasing strength blindly.

Company profile

About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Sector
Healthcare
Industry
Medical - Specialties
CEO
Uzi Sofer
Employees
121
Market cap
$959.0M
Beta
1.17
52-week range
$0.33 – $3.30
Dividend
No
Exchange
NASDAQ
Country
IL
IPO date
6 Mar 2026
ISIN
IL0011839466
CUSIP
M0740A116
Company profile data from Financial Modeling Prep. DRTSW listed on NASDAQ.
Share dilution

DRTSW shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
89.7M
Since Jun 2019
+32.7%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. DRTSW28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about DRTSW

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.